NasdaqGS - Nasdaq Real Time Price USD

Rallybio Corporation (RLYB)

0.3618
+0.0148
+(4.27%)
As of 12:01:49 PM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
848
636
0
0
0
Operating Expense
51,227
61,132
78,932
67,884
45,648
Operating Income
-50,379
-60,496
-78,932
-67,884
-45,648
Net Non Operating Interest Income Expense
3,584
4,216
6,147
1,963
44
Other Income Expense
-1,390
-1,495
-1,779
-733
96
Pretax Income
-48,185
-57,775
-74,564
-66,654
-45,508
Tax Provision
--
--
--
--
0
Earnings from Equity Interest Net of Tax
--
--
--
-1,075
-1,505
Net Income Common Stockholders
-48,185
-57,775
-74,564
-66,654
-47,013
Diluted NI Available to Com Stockholders
-48,185
-57,775
-74,564
-66,654
-47,013
Basic EPS
-1.07
--
-1.84
-2.09
-1.84
Diluted EPS
-1.07
--
-1.84
-2.09
-1.84
Basic Average Shares
44,545.0710
--
40,447.3880
31,821.3110
25,519.1140
Diluted Average Shares
44,545.0710
--
40,447.3880
31,821.3110
25,519.1140
Total Operating Income as Reported
-50,379
-60,496
-78,932
-67,884
-45,648
Total Expenses
51,227
61,132
78,932
67,884
45,648
Net Income from Continuing & Discontinued Operation
-48,185
-57,775
-74,564
-66,654
-47,013
Normalized Income
-48,185
-57,775
-74,564
-66,654
-47,013
Interest Income
3,584
4,216
6,147
1,963
54
Interest Expense
--
--
--
0
10
Net Interest Income
3,584
4,216
6,147
1,963
44
EBIT
-50,379
-60,496
-78,932
-67,884
-45,498
EBITDA
-50,255
-60,365
-78,782
-67,717
-45,389
Reconciled Depreciation
124
131
150
167
109
Net Income from Continuing Operation Net Minority Interest
-48,185
-57,775
-74,564
-66,654
-47,013
Normalized EBITDA
-50,255
-60,365
-78,782
-67,717
-45,389
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 7/29/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

TYRA Tyra Biosciences, Inc.
10.01
+3.36%
 
VIGL Vigil Neuroscience, Inc.
2.6100
+4.82%
 
ACRV Acrivon Therapeutics, Inc.
1.2000
+1.69%
 
PEPG PepGen Inc.
1.5050
+1.01%
 
GLUE Monte Rosa Therapeutics, Inc.
4.0900
-0.49%
 
CGEM Cullinan Therapeutics, Inc.
7.78
+0.91%
 
IMRX Immuneering Corporation
1.5050
-0.99%
 
DSGN Design Therapeutics, Inc.
3.5750
+1.28%
 
PULM Pulmatrix, Inc.
6.53
+1.08%
 
OVID Ovid Therapeutics Inc.
0.2901
-3.65%